Literature DB >> 22484031

Rosuvastatin improves pulse wave reflection by restoring endothelial function.

C Ott1, M P Schneider, M P Schlaich, R E Schmieder.   

Abstract

One of the major indicators of intact endothelial function is basal nitric oxide (NO) activity. Further, it seems to be likely that statin therapy exerts beneficial effects on vascular function, at least in part via an improvement of NO bioavailability. In the present double-blind crossover study 29 hypercholesterolemic patients were randomly assigned to receive rosuvastatin and placebo for 42days. Pulse wave analysis was assessed after 30min of rest (baseline) and after infusion of N(G)-monomethyl-l-arginine (l-NMMA) at the end of 42days treatment period. The magnitude of the increase in central augmentation index (cAIx) in response to inhibition of NO synthase (NOS) by l-NMMA is indicative of basal NO activity. CAIx was significantly lower (18.3±10 versus 21.9±12%, p=0.027) with rosuvastatin compared to placebo. There was no increment of cAIx in response to l-NMMA in placebo group. In contrast, cAIx increased significantly in response to l-NMMA (20.5±11 versus 25.7±10mm Hg, p=0.001) in rosuvastatin group. The percentage of increase of cAIx tended to be more pronounced after treatment with rosuvastatin compared to placebo (53.7±92 versus 14.1±36%, p=0.087). Pulse pressure amplification (PPA) improved (1.31±0.2 versus 1.26±0.2%, p=0.016) after rosuvastatin compared to placebo. Regression analyses revealed that both LDL-cholesterol and CRP-levels are independent determinants of basal NO activity improvement, which itself is an independent determinant of vascular function, expressed by an improvement of pulse wave reflection and PPA. In this placebo controlled study, treatment with rosuvastatin improved vascular and endothelial function. Determinants for improved NO production in patients with hypercholesterolemia were the achieved levels of LDL-cholesterol and CRP. Overall, in patients without CV disease, rosuvastatin exerted beneficially effect on vascular dysfunction, one of the earliest manifestation of atherosclerosis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484031     DOI: 10.1016/j.mvr.2012.03.007

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  6 in total

1.  Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.

Authors:  Sonam Kathuria; Nanjaian Mahadevan; Pitchai Balakumar
Journal:  Mol Cell Biochem       Date:  2012-11-10       Impact factor: 3.396

2.  Prospective risk factors for increased central augmentation index in men and women.

Authors:  Prithvi Shiva Kumar; Josefina Medina-Lezama; Oscar Morey-Vargas; Payman Zamani; Juan F Bolaños-Salazar; Diana A Chirinos; Philip Haines; Zubair A Khan; Johanna C Coacalla-Guerra; Maria E Davalos-Robles; Gladys R Llerena-Dongo; Mardelangel Zapata-Ponze; Julio A Chirinos
Journal:  Am J Hypertens       Date:  2014-05-28       Impact factor: 2.689

3.  Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.

Authors:  Frank Holden Mose; Thomas Larsen; Janni Majgaard Jensen; Annebirthe Bo Hansen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

4.  Effects of Atorvastatin on Resting and Peak Exercise Blood Pressure among Normotensive Men and Women.

Authors:  Amanda L Zaleski; Marianne L Mentch; Linda S Pescatello; Beth A Taylor; Jeffrey A Capizzi; Adam S Grimaldi; Priscilla M Clarkson; Stephanie A Moeckel-Cole; Stuart R Chipkin; Justin Keadle; Charles Michael White; Paul D Thompson
Journal:  Cholesterol       Date:  2014-11-18

Review 5.  Beneficial Effect of Statin Therapy on Arterial Stiffness.

Authors:  Mona Alidadi; Fabrizio Montecucco; Tannaz Jamialahmadi; Khalid Al-Rasadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Biomed Res Int       Date:  2021-03-30       Impact factor: 3.411

6.  Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia.

Authors:  Congwu Huang; Chuan Cen; ChengXu Wang; Haiyong Zhan; Xin Ding
Journal:  Lipids Health Dis       Date:  2014-04-17       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.